- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Ono Pharmaceutical GAAP EPS of ¥ 51.38, revenue of ¥ 116.1B | 1 | Seeking Alpha | ||
| Fr | Ono Pharmaceutical Co Ltd. Q1 Income Advances | 1 | RTTNews | ||
| 27.07. | Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline | 4 | Zacks | ||
| 27.07. | Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength? | 1 | Zacks | ||
| 28.05. | Jefferies raises Ono Pharmaceutical price target on pipeline outlook | 3 | Investing.com | ||
| 08.05. | Ono Pharmaceutical reports FY results | 5 | Seeking Alpha | ||
| ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 08.05. | Ono Pharmaceutical Co. Ltd. Full Year Profit Climbs | 3 | RTTNews | ||
| 26.03. | Ono Pharma Submits Application For Manufacturing And Marketing Approval Of Ripretinib | 428 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical (4528.T) announced that it has submitted an application for the manufacturing and marketing approval of ripretinib or DCC-2618, developed... ► Artikel lesen | |
| 02.02. | Ono Pharmaceutical Co. Ltd. Reveals Climb In Nine Months Bottom Line | 531 | AFX News | TOKYO (dpa-AFX) - Ono Pharmaceutical Co. Ltd. (OPHLF) released a profit for its nine months that Increases, from the same period last yearThe company's earnings came in at JPY68.949 billion... ► Artikel lesen | |
| 14.01. | Ono Pharma Taiwan Receives Additional Approval Of Opdivo In Combination With Ipilimumab | 525 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical Co. announced that Ono Pharma Taiwan Co., a Taiwanese subsidiary of Ono, received the additional approval of Opdivo Intravenous Infusion... ► Artikel lesen | |
| 30.10.25 | Ono Pharmaceutical H1 Results Improve; Backs Annual Guidance | 538 | AFX News | TOKYO (dpa-AFX) - Ono Pharmaceutical Co., Ltd.(OPHLF, 4528.T) on Thursday reported a rise in earnings and revenue for the first half. In addition, the company has reaffirmed its annual outlook.For... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 113,32 | +0,35 % | Cantor Fitzgerald reiterates Gilead Sciences stock rating at Overweight | ||
| CANOPY GROWTH | 0,790 | -0,65 % | Drama um Canopy, Tilray & Co?: Anhörungsprozess zu Cannabis endet - Stürzt die DEA den Sektor ins Chaos? | © Foto: adobe.stock.comAm 29. Juni begann der Anhörungsprozess der DEA zur möglichen Neueinstufung von Freizeit-Cannabis in Schedule III. Mittlerweile steht der Anhörungsprozess vor seinem Ende. Was... ► Artikel lesen | |
| MERCK & CO | 113,26 | +0,28 % | Dividend Roundup: Wells Fargo, Merck, Citigroup, Carnival Corp, and more | ||
| JAGUAR HEALTH | 1,010 | +1,00 % | Jaguar Health, Inc.: Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog | Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 403,90 | -0,37 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Second-quarter 2026 Rezdiffra- (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling... ► Artikel lesen | |
| IQVIA | 202,30 | -0,78 % | ROUNDUP: IQVIA Holdings Boosts FY26 Outlook; Shares Surge 10.6% | WASHINGTON (dpa-AFX) - While reporting financial results for the second quarter on Tuesday, life sciences services company IQVIA Holdings Inc. (IQV) raised its adjusted earnings and revenue... ► Artikel lesen | |
| AZENTA | 25,000 | +2,46 % | Azenta Completes Sale of B Medical Systems | BURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems... ► Artikel lesen | |
| ALMIRALL | 11,260 | +1,26 % | Almirall, S.A.: Almirall H1 2026 Results | Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business reiterating guidance aligned with long-term growth trajectory... ► Artikel lesen | |
| PROTHENA | 7,004 | -0,48 % | Prothena Corporation plc: Prothena to Report Second Quarter 2026 Financial Results on August 6 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| SPROUTLY CANADA | - | - | CSE Bulletin: Delist - Sproutly Canada Inc. (SPR) | Le 22 mai/May 2026
The common shares of Sproutly Canada Inc will be delisted from the CSE at market close today, May 22, 2026.
Sproutly Canada Inc. is currently suspended. See Bulletin 2022-0908.
___________________________
Les... ► Artikel lesen | |
| PETIQ | - | - | PetIQ Acquires MYOS To Expand Pet Muscle Health And Mobility Portfolio | ||
| FUJI PHARMA | 10,100 | +1,00 % | Dividendenbekanntmachungen (30.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 113 JPY 0,6124 EUR ACOM CO LTD JP3108600002 10 JPY 0,0542 EUR ADAMAS TRUST INC US6496048405 0,23 USD 0... ► Artikel lesen | |
| FINANCIERE DE TUBIZE | 196,30 | +1,03 % | Financière de Tubize SA: Financière de Tubize - Dividend approval | Dividend confirmationRegulated information - 24 April 2026
The general shareholders meeting of 24 April 2026 has approved the annual accounts as at 31 December 2025, including the distribution of... ► Artikel lesen | |
| BAYER | 48,050 | -0,81 % | Bayer: Ende der Korrektur noch nicht bestätigt | Nach den jüngsten Gewinnmitnahmen ist die Bayer-Aktie aus ihrer Konsolidierung nach oben ausgebrochen. Das verhaltene Handelsvolumen liefert bislang jedoch noch keine vollständige Bestätigung der Bewegung... ► Artikel lesen | |
| MERCK KGAA | 143,15 | +0,21 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher ausgegebener Aktien an und alleiniger Kontrolle über Bio-Techne Corporation, Minneapolis, MN/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-84/26Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher ausgegebener Aktien an und alleiniger Kontrolle über Bio-Techne Corporation, Minneapolis, MN/USAProduktmärkte:Antikörper... ► Artikel lesen |
ONO PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,240 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONO PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.